C4 Therapeutics, Inc. (CCCC) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, C4 Therapeutics reported revenue of $35.9M, up 1.0% from $35.6M the year before. Net income was -$105.0M (a -292.1% net margin), or -$1.27 per diluted share. Operating margin was -320.5%. Operating activities generated -$98.7M of cash, leaving -$99.3M of free cash flow. At fiscal year end, C4 Therapeutics held $359.1M in total assets against $102.5M in total liabilities, including $74.6M of cash and equivalents.
Open the full interactive C4 Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
C4 Therapeutics Key Stats
| Share Price | $2.78 |
|---|---|
| Market Cap | $363.3M |
| Revenue YoY Growth | +1.0% |
| 52-Week Range | $1.71 – $4.67 |
| Shares Outstanding | 130.7 million (basic, 2026 Q2) |
C4 Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $31.1M | $20.8M | $35.6M | $35.9M |
| Operating Income | -$60.4M | -$82.1M | -$129.5M | -$139.0M | -$119.6M | -$115.2M |
| Pre-Tax Income | -$67.0M | -$83.9M | -$128.2M | -$131.2M | -$105.2M | -$104.9M |
| Income Tax | -$626,000 | — | $0 | $1.3M | $131,000 | $121,000 |
| Net Income | -$66.3M | -$83.9M | -$128.2M | -$132.5M | -$105.3M | -$105.0M |
| Diluted EPS | -$5.83 | -$1.82 | -$2.62 | -$2.67 | -$1.52 | -$1.27 |
C4 Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $11.2M | $11.0M | $6.2M | $6.6M |
| Net Income | -$32.2M | -$20.5M | -$25.1M | -$23.6M |
| Diluted EPS | -$0.44 | -$0.25 | -$0.20 | -$0.18 |
C4 Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $181.7M | $76.1M | $29.8M | $126.6M | $55.5M | $74.6M |
| Current Assets | $381.0M | $325.7M | $287.6M | $271.2M | $257.8M | $258.1M |
| Total Assets | $400.1M | $506.8M | $430.8M | $376.5M | $349.6M | $359.1M |
| Current Liabilities | $43.9M | $51.2M | $44.5M | $42.8M | $45.2M | $33.0M |
| Total Long-Term Debt | $10.1M | $10.8M | $11.5M | — | — | — |
| Total Liabilities | $119.3M | $117.2M | $141.6M | $130.3M | $133.6M | $102.5M |
| Shareholders' Equity | $280.8M | $389.6M | $289.2M | $246.1M | $216.0M | $256.6M |
C4 Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$67.2M | -$87.0M | -$105.9M | -$106.8M | -$65.2M | -$98.7M |
| Cash From Investing | -$190.5M | -$189.3M | $58.4M | $158.3M | -$51.3M | -$8.6M |
| Cash From Financing | $348.9M | $171.4M | $1.1M | $45.5M | $45.3M | $126.4M |
| Free Cash Flow | -$67.9M | -$88.2M | -$111.4M | -$108.5M | -$65.3M | -$99.3M |
Figures from C4 Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full C4 Therapeutics financials page for every line item.
C4 Therapeutics Company Profile
| Ticker | CCCC |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Watertown, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001662579 |
Frequently Asked Questions
What was C4 Therapeutics' revenue in fiscal 2025?
C4 Therapeutics (CCCC) reported revenue of $35.9M for fiscal 2025.
What is C4 Therapeutics' annual revenue history?
C4 Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $31.1M; 2023: $20.8M; 2024: $35.6M; 2025: $35.9M.
What was C4 Therapeutics' net income in fiscal 2025?
C4 Therapeutics reported net income of -$105.0M for fiscal 2025.
What was C4 Therapeutics' earnings per share (EPS) in fiscal 2025?
C4 Therapeutics' diluted EPS was -$1.27 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did C4 Therapeutics generate in fiscal 2025?
C4 Therapeutics generated -$99.3M of free cash flow in fiscal 2025.
What was C4 Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), C4 Therapeutics reported revenue of $6.6M.
How many shares of C4 Therapeutics are outstanding?
C4 Therapeutics reported a weighted average of 130.7 million basic shares outstanding in 2026 Q2.
What is C4 Therapeutics' market cap?
Based on its latest closing price, C4 Therapeutics (CCCC) has a market capitalization of about $363.3M.
When does C4 Therapeutics' fiscal year end?
C4 Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is C4 Therapeutics headquartered?
C4 Therapeutics lists its business address in Watertown, Massachusetts in its SEC filings.
C4 Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →